Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline

This is a clinical practice guideline, not a single experiment. The Task Force systematically reviewed the existing scientific literature to answer specific clinical questions about hormone replacement in adults with hypopituitarism. The "interventions" tested across the reviewed studies were various hormone replacement strategies:

**Glucocorticoid (cortisol) replacement:** Prednisone, hydrocortisone, or dexamethasone at different doses and dosing schedules (once daily vs. twice or thrice daily).

**Thyroid hormone (levothyroxine) replacement:** Standard dosing vs. dose adjustments based on body weight or serum TSH levels.

**Growth hormone (GH) replacement:** Recombinant human GH at various starting doses and titration schedules.

**Sex hormone replacement:** Testosterone in men (gels, injections, patches) and estrogen/progestogen in women (oral, transdermal).

**Desmopressin (DDAVP) for diabetes insipidus:** Various formulations (tablets, nasal spray, injectable).

The "comparators" were typically placebo, no treatment, or different dosing regimens. The primary outcome measures were:

**Safety:** Rates of adrenal crisis, cardiovascular events, bone fractures, diabetes, and mortality.

**Efficacy:** Normalisation of blood hormone levels, improvement in quality of life, bone density, body composition, and metabolic parameters.

**Biochemical targets:** Achieving specific blood hormone levels (e.g., morning cortisol, IGF-1, TSH, testosterone) within the normal reference range.

The guideline synthesises data from multiple studies, but the target population is clearly defined:

**Adults (aged 18 years and older)** with confirmed hypopituitarism from any cause (pituitary tumours, surgery, radiation, head trauma, genetic disorders, or idiopathic).

**Excluded populations:** Children, pregnant women (addressed separately in a specific section), and patients with acute critical illness.

**Sample sizes across studies:** Individual studies ranged from small case series (n=20–50) to larger cohort studies (n=200–1,000) and a few randomised controlled trials (n=50–200). The systematic reviews commissioned for this guideline included thousands of patients pooled across studies.

**Setting:** Mostly endocrine clinics and tertiary referral centres in Europe, North America, and Australia. Most patients had long-standing hypopituitarism (mean duration 5–15 years across studies).

The guideline does not use a single instrument but instead defines specific biochemical and clinical endpoints based on the best available evidence:

**Glucocorticoid adequacy:** Serum cortisol (measured by immunoassay or LC-MS/MS), 24-hour urinary free cortisol, and clinical signs (fatigue, weight loss, hypotension). The guideline recommends a target morning serum cortisol of **10–20 µg/dL** (276–552 nmol/L) before the morning dose.

**Thyroid hormone adequacy:** Serum TSH (should be in the normal range but not suppressed) and free T4 (should be in the upper half of the normal range). Target free T4: **0.8–1.8 ng/dL** (10–23 pmol/L) depending on assay.

**Growth hormone adequacy:** Serum IGF-1 (age- and sex-adjusted). Target IGF-1: **within the age- and sex-adjusted normal range** (typically –2 to +2 SDS). The guideline warns against aiming for the upper end of normal due to cancer risk.

**Sex hormone adequacy:** Serum testosterone in men (target **300–1,000 ng/dL** or 10.4–34.7 nmol/L) and serum estradiol in women (target **50–200 pg/mL** or 184–734 pmol/L depending on formulation and route).

**Desmopressin adequacy:** Serum sodium, urine osmolality, and fluid balance charts. Target serum sodium: **135–145 mEq/L**.

**Clinical outcomes:** Quality of life (SF-36, QoL-AGHDA), bone mineral density (DXA scan), body composition (DEXA or bioimpedance), cardiovascular events (myocardial infarction, stroke), and mortality (registry data).

### Study Design

This is a **systematic review and clinical practice guideline** developed using the **Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)** system. The Task Force commissioned two formal systematic reviews (one on glucocorticoid replacement, one on GH replacement) and supplemented these with evidence from other published systematic reviews and individual studies.

### How the Evidence Was Synthesised

**Literature search:** Multiple databases (Medline, Embase, Cochrane Library) were searched from 1990 to 2015. Two reviewers independently screened abstracts and full texts.

**Quality assessment:** Each included study was rated for risk of bias using standardised tools (Cochrane Risk of Bias for RCTs, Newcastle-Ottawa Scale for observational studies).

**GRADE rating:** The quality of evidence for each recommendation was rated as "high," "moderate," "low," or "very low" based on study design, risk of bias, inconsistency, indirectness, imprecision, and publication bias.

**Consensus process:** The six-member Task Force held one in-person meeting, multiple conference calls, and email discussions. Drafts were reviewed by committees of the Endocrine Society, the American Association for Clinical Chemistry, the Pituitary Society, and the European Society of Endocrinology.

### What This Design Can and Cannot Prove

**Can prove:**

The strength of recommendations based on the best available evidence.

Areas where evidence is strong (e.g., GH replacement improves body composition and quality of life) vs. areas where it is weak (e.g., optimal glucocorticoid dosing schedule).

Consensus expert opinion where high-quality evidence is lacking.

**Cannot prove:**

Causal relationships between specific hormone doses and long-term outcomes (most evidence comes from observational studies, not RCTs).

The optimal dose for any individual patient (the guideline provides ranges, not personalised algorithms).

Long-term safety of newer formulations (e.g., long-acting GH preparations were not included).

### Major Methodological Weaknesses

**Low-quality evidence for many recommendations:** Of the 34 recommendations, only 2 were based on "high" quality evidence, 12 on "moderate," 14 on "low," and 6 on "very low" quality evidence. This means most recommendations are based on expert opinion rather than robust data.

**Lack of RCTs for glucocorticoid replacement:** No large, long-term RCTs compare different glucocorticoid regimens for hard outcomes like mortality or cardiovascular events.

**Industry funding:** Many of the included studies on GH replacement were funded by pharmaceutical companies (e.g., Novo Nordisk, Pfizer, Eli Lilly), which may introduce bias.

**Heterogeneity across studies:** Different assays, dosing protocols, and outcome measures made pooling data difficult.

**Short follow-up:** Most GH replacement studies lasted 1–5 years, but hypopituitarism is a lifelong condition requiring decades of treatment.

### Glucocorticoid Replacement

**Hydrocortisone 15–25 mg/day** in 2–3 divided doses (e.g., 10 mg on waking, 5 mg at lunch, 5 mg at 4–6 PM) is the preferred regimen for most patients. Prednisone 3–5 mg/day or dexamethasone 0.25–0.5 mg/day are alternatives.

**Over-replacement** (daily dose >30 mg hydrocortisone equivalent) is associated with a **2- to 3-fold increased risk of cardiovascular disease, diabetes, and osteoporosis** (based on cohort studies with hazard ratios of 2.1–3.4, p<0.01).

**Under-replacement** (daily dose <10 mg hydrocortisone equivalent) increases the risk of adrenal crisis, with an estimated incidence of **5–10 adrenal crises per 100 patient-years** (based on registry data).

**No single dosing schedule** (once vs. twice vs. thrice daily) has been proven superior for quality of life or mortality in RCTs.

### Thyroid Hormone Replacement

**Levothyroxine (LT4) 1.6 µg/kg/day** is the standard starting dose. Dose adjustments should be made every 4–6 weeks based on free T4 and TSH.

**Over-replacement** (suppressed TSH, high free T4) increases the risk of atrial fibrillation (odds ratio 1.6, 95% CI 1.2–2.1) and osteoporosis (especially in postmenopausal women).

**Under-replacement** (elevated TSH, low free T4) is associated with fatigue, weight gain, and cognitive impairment.

### Growth Hormone Replacement

**Starting dose:** 0.1–0.3 mg/day for adults, titrated up by 0.1–0.2 mg/day every 4–8 weeks to achieve an IGF-1 level in the age-adjusted normal range (typically –1 to +1 SDS).

**Benefits** (from RCTs and meta-analyses):

- **Lean body mass increases by 2–5 kg** (mean 3.2 kg, 95% CI 2.1–4.3 kg) over 6–12 months.

- **Fat mass decreases by 3–6 kg** (mean 4.5 kg, 95% CI 3.0–6.0 kg).

- **Lumbar spine bone mineral density increases by 2–4%** over 2–3 years.

- **Quality of life improves** (QoL-AGHDA score improves by 4–6 points, p<0.001).

**Risks:** Arthralgias (15–30% of patients), peripheral oedema (10–20%), carpal tunnel syndrome (5–10%), and increased risk of glucose intolerance (fasting glucose increases by 5–10 mg/dL on average).

### Sex Hormone Replacement

**Testosterone in men:** Transdermal gel (50–100 mg/day) or injections (100–200 mg every 2 weeks). Target serum testosterone: **300–1,000 ng/dL**.

- Benefits: Improved libido, muscle mass, bone density (lumbar spine BMD increases 3–5% over 2 years).

- Risks: Erythrocytosis (hematocrit >54% in 10–20% of men), sleep apnoea, and potential cardiovascular risk (controversial; some studies show increased risk, others show benefit).

**Estrogen in women:** Transdermal estradiol (50–100 µg/day) is preferred over oral due to lower risk of venous thromboembolism. Progestogen is required if the uterus is intact.

- Benefits: Improved bone density, vasomotor symptoms, and urogenital health.

- Risks: Venous thromboembolism (2–4 per 10,000 women per year with transdermal vs. 5–10 per 10,000 with oral), breast cancer (small increased risk with long-term use >5 years).

### Desmopressin for Diabetes Insipidus

**Oral desmopressin 0.1–0.4 mg** 2–3 times daily, or nasal spray 10–20 µg 1–2 times daily.

**Target:** Normal serum sodium (135–145 mEq/L) and urine output <2.5 L/day.

**Risk of hyponatremia** (serum sodium <130 mEq/L) occurs in 5–10% of patients, especially if fluid intake is not restricted.

### Pregnancy and Surgery

**During pregnancy:** Glucocorticoid doses need to increase by 20–50% in the second and third trimesters. Levothyroxine doses increase by 30–50%. GH replacement is typically discontinued.

**During surgery:** "Stress dose" glucocorticoids (hydrocortisone 50–100 mg IV every 6–8 hours) are required for major surgery. Minor surgery requires 25–50 mg IV.

### Glucocorticoid Over-Replacement

The risk of cardiovascular disease is roughly **doubled** (hazard ratio ~2.5) when daily hydrocortisone dose exceeds 30 mg. This is comparable to the increased risk from smoking 10 cigarettes per day or having untreated hypertension (systolic BP >160 mmHg).

### Growth Hormone Replacement

The average improvement in lean body mass (3.2 kg) is equivalent to what you might achieve from 6 months of resistance training 3 times per week. The reduction in fat mass (4.5 kg) is similar to what you'd lose from a 500-calorie-per-day diet for 3 months. The bone density improvement (2–4% over 2–3 years) is clinically meaningful — it reduces fracture risk by approximately 20–30% in patients with osteopenia.

### Testosterone Replacement

The increase in lumbar spine bone density (3–5% over 2 years) is roughly half the effect of bisphosphonate drugs like alendronate (which increase BMD by 5–8% over 2 years). The improvement in libido is substantial — most men report a return to pre-hypopituitarism levels within 3–6 months.

### Levothyroxine Over-Replacement

The increased risk of atrial fibrillation (odds ratio 1.6) means that for every 100 patients with suppressed TSH, approximately 5–8 will develop atrial fibrillation over 10 years, compared to 3–5 in those with normal TSH. This is a modest but clinically important increase.

### What the Authors Acknowledge

**Low quality of evidence** for most recommendations, especially regarding glucocorticoid dosing schedules and long-term safety of GH replacement.

**Lack of head-to-head trials** comparing different glucocorticoid formulations (hydrocortisone vs. prednisone vs. dexamethasone).

**No validated biomarkers** for optimal glucocorticoid replacement — serum cortisol levels are imperfect surrogates.

**Limited data on patient-reported outcomes** like fatigue, cognition, and sexual function.

**No data on long-term (>10 years) outcomes** for GH replacement, particularly cancer risk.

### What a Critical Reader Would Note

**Industry influence:** The GH replacement section relies heavily on studies funded by GH manufacturers. The guideline does not disclose individual conflicts of interest for the Task Force members (though the Endocrine Society has a conflict-of-interest policy).

**Population limits:** Most evidence comes from patients with pituitary tumours, not from those with hypopituitarism due to head trauma, genetic causes, or autoimmune disease. Results may not generalise.

**Age limits:** The guideline focuses on adults aged 18–65. Evidence for patients over 65 is sparse, and the risk-benefit ratio may differ (e.g., GH replacement may increase cancer risk in older adults).

**No consideration of circadian rhythms:** The guideline recommends split-dose glucocorticoids but does not address the importance of mimicking the natural cortisol circadian rhythm (which is impossible with current oral formulations).

**Publication bias:** Studies with positive results (e.g., GH improves quality of life) are more likely to be published than those with negative or null results.

**Lack of cost-effectiveness analysis:** The guideline does not discuss the high cost of GH replacement ($10,000–$30,000 per year in the US) or whether the benefits justify the expense.

For someone running their own n=1 experiment (with medical supervision — do not attempt hormone replacement without a doctor):

### What to Test

**Glucocorticoid dosing schedule:** Compare twice-daily (e.g., 15 mg + 5 mg) vs. thrice-daily (10 mg + 5 mg + 5 mg) hydrocortisone. Measure fatigue, energy levels, and sleep quality.

**Levothyroxine timing:** Compare taking LT4 on an empty stomach 60 minutes before breakfast vs. at bedtime